This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Merck to Buy Private Cancer Drugmaker Peloton Therapeutics
by Zacks Equity Research
Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.
Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL
by Zacks Equity Research
Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid
by Zacks Equity Research
Celgene (CELG) obtains approval for the label expansion of oncology drugs Revlimid and Imnovid in Europe.
Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer
by Zacks Equity Research
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
Zacks.com featured highlights include: BlackRock, Northrop, Progressive, Interpublic Group and Bristol-Myers
by Zacks Equity Research
Zacks.com featured highlights include: BlackRock, Northrop, Progressive, Interpublic Group and Bristol-Myers
Buy These 5 Stocks With Impressive Sales Growth Right Away
by Swayta Shah
Sales growth is a key measure for any company, as it is important for growth projections and strategic decision making.
Bristol-Myers (BMY) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Bristol-Myers (BMY) could produce exceptional returns because of its solid growth attributes.
AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.
AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.
Endo (ENDP) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Endo's (ENDP) earnings and revenues top expectations in the first quarter of 2019.
Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y
by Zacks Equity Research
Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.
Zacks.com featured highlights include: Exantas Capital, Lamb Weston, Bristol-Myers Squibb, Amedisys and Computer Programs and Systems
by Zacks Equity Research
Zacks.com featured highlights include: Exantas Capital, Lamb Weston, Bristol-Myers Squibb, Amedisys and Computer Programs and Systems
Why Bristol-Myers Squibb (BMY) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Mallinckrodt (MNK) Beats on Q1 Earnings & Sales, Raises View
by Zacks Equity Research
Mallinckrodt (MNK) earnings and sales surpass estimates in the first quarter, which led to an increase in annual guidance.
Aerie (AERI) Q1 Earnings Beat, Rhopressa Misses Estimates
by Zacks Equity Research
Aerie (AERI) reports narrower-than-expected Q1 loss. However, Rhopressa lags expectations.
Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Aduro (ADRO) suspends the BION-1301 program for MM in Q1 due to severe competition.
Array BioPharma (ARRY) Q3 Earnings and Sales Beat Estimates
by Zacks Equity Research
Array BioPharma's (ARRY) top and bottom lines beat estimates in the third quarter of fiscal 2019. Momentum in uptake of Braftovi-Mektovi combination therapy continues.
Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong
by Zacks Equity Research
Clovis (CLVS) reports encouraging first-quarter 2019 results. Rubraca maintains market share during the quarter.
Infinity (INFI) Earnings and Sales Miss Estimates in Q1
by Zacks Equity Research
Infinity (INFI) posts wider-than-expected loss in the first quarter of 2019. Sales miss estimates in the quarter.
Prothena's (PRTA) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Prothena's (PRTA) Q1 loss was narrower than expected, while revenues missed expectations.
5 ROE Stocks to Profit as Trade Woes Shake Equity Markets
by Supriyo Bose
ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.
5 Stocks With Upgraded Broker Ratings Worth Betting on Now
by Swayta Shah
Brokers have more understanding of fundamentals of a company, and also about the overall economy. So, following broker advice is a wise decision.
Bet on Top Stocks With Rising P/E to Enjoy Solid Gains
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
What's in the Cards for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
The focus will be on Nektar Therapeutics' (NKTR) pipeline progress when the company reports first-quarter results.
Will Higher Expenses Dent Cronos' (CRON) Earnings in Q1?
by Zacks Equity Research
Apart from the regular top and bottom-line numbers, investors will focus on Cronos' (CRON) pipeline progress, when it reports Q1 results.